Henrik Schultz

3.6k total citations · 1 hit paper
57 papers, 2.6k citations indexed

About

Henrik Schultz is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Henrik Schultz has authored 57 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Surgery, 15 papers in Pulmonary and Respiratory Medicine and 11 papers in Genetics. Recurrent topics in Henrik Schultz's work include Testicular diseases and treatments (19 papers), Glioma Diagnosis and Treatment (11 papers) and Ovarian cancer diagnosis and treatment (7 papers). Henrik Schultz is often cited by papers focused on Testicular diseases and treatments (19 papers), Glioma Diagnosis and Treatment (11 papers) and Ovarian cancer diagnosis and treatment (7 papers). Henrik Schultz collaborates with scholars based in Denmark, Saudi Arabia and United States. Henrik Schultz's co-authors include Roger Stupp, Christine Marosi, Bjørn Henning Grønberg, Annika Malmström, Didier Frappaz, Roger Henriksson, Monika E. Hegi, Benoît Lhermitte, Ufuk Abacıoğlu and Johan Rosell and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Henrik Schultz

53 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

2012 866 citations Annika Malmström, Bjørn Henning Grønberg et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Henrik Schultz

Since Specialization

Citations

This map shows the geographic impact of Henrik Schultz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henrik Schultz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henrik Schultz more than expected).

Fields of papers citing papers by Henrik Schultz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henrik Schultz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henrik Schultz. The network helps show where Henrik Schultz may publish in the future.

Co-authorship network of co-authors of Henrik Schultz

This figure shows the co-authorship network connecting the top 25 collaborators of Henrik Schultz. A scholar is included among the top collaborators of Henrik Schultz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henrik Schultz. Henrik Schultz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Putting the PASC Score to the Test: Clinical vs. Statistical Accuracy in Long COVID Diagnosis 2025 ·Journal of General Internal Medicine ·Alba Azola, Raha Dastgheyb, (unknown), Hannah Parker, Cláudia Penna, (unknown), Henrik Schultz, (unknown), Rebecca T. Veenhuis, Leah H. Rubin	0
2	DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome—including in elderly patients 2022 ·Acta Neuropathologica Communications ·Pierre Bady, Christine Marosi, Michael Weller, Bjørn Henning Grønberg, Henrik Schultz, Martin Taphoorn, Johanna M. M. Gijtenbeek, Martin J. van den Bent, Andreas von Deimling, Roger Stupp, Annika Malmström, Monika E. Hegi	8
3	Identifying particular places through experimental walking 2016 ·SHILAP Revista de lepidopterología ·Henrik Schultz	0
4	Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study 2014 ·Acta Oncologica ·Kenneth Francis Hofland, Steinbjørn Hansen, Morten Mau‐Sørensen, Silke Engelholm, Henrik Schultz, Aida Muhic, Kirsten Grunnet, (unknown), Junia C. Costa, Charlotte Kristiansen, Carsten Thomsen, Hans Skovgaard Poulsen, Ulrik Lassen	24
5	A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy 2012 ·Acta Oncologica ·Søren Møller, Kirsten Grunnet, Steinbjørn Hansen, Henrik Schultz, Mats Holmberg, Morten Mau‐Sørensen, Hans Skovgaard Poulsen, Ulrik Lassen	47
6	Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial breakdown → 2012 ·The Lancet Oncology ·Annika Malmström, Bjørn Henning Grønberg, Christine Marosi, Roger Stupp, Didier Frappaz, Henrik Schultz, Ufuk Abacıoğlu, Björn Tavelin, Benoît Lhermitte, Monika E. Hegi, Johan Rosell, Roger Henriksson	866
7	A novel DNAseq program for enhanced analysis of Illumina GAII data: a case study on antibody complementarity-determining regions 2011 ·New Biotechnology ·(unknown), Henrik Schultz, Niels H. H. Heegaard, Mingyue He	1
8	Randomized phase II study of neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed primary glioblastoma multiforme. 2011 ·Journal of Clinical Oncology ·Kenneth Francis Hofland, (unknown), (unknown), Henrik Schultz, Aida Muhic, (unknown), Anna Ask, Charlotte Kristiansen, (unknown), Hans Skovgaard Poulsen, Ulrik Lassen	2
9	Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma 2009 ·British Journal of Cancer ·David A. Reardon, G. Dresemann, Sophie Taillibert, Mario Campone, Martin J. van den Bent, Paul M. Clément, Erik Blomquist, Laurence Gordower, Henrik Schultz, Jeffrey Raizer, Peter Hau, Jacob C. Easaw, (unknown), J.-C. Tonn, Anja Gijtenbeek, Uwe Schlegel, Per Bergström, (unknown), Alexander Weir, Zariana Nikolova	100
10	Optic gliomas: A retrospective analysis of 50 cases 2003 ·International Journal of Radiation OncologyBiologyPhysics ·Yasser Khafaga, Maher Hassounah, (unknown), Imaduddin Kanaan, Ayman Allam, Gamal El-Husseiny, Amani Kofide, (unknown), (unknown), Henrik Schultz, Derek Jenkin	51
11	Metastatic Ewing sarcoma/PNET of bone at diagnosis: Prognostic factors—a report from Saudi Arabia 2001 ·Medical and Pediatric Oncology ·R. D. T. Jenkin, I. Al‐Fawaz, (unknown), Ayman Allam, Mouhab Ayas, Muhammad Ali Memon, (unknown), Henrik Schultz	16
12	The Saudi experience with neutron therapy in locally advanced head and neck cancers 1996 ·PubMed ·A.D. Flores, (unknown), Arif Jamshed, Yasser Khafaga, Henrik Schultz, A.Y. Rostom, (unknown), (unknown), (unknown), Edward B. De Vol, (unknown)	4
13	Moyamoya Vasculopathy After Cranial Irradiation—a Case Report 1995 ·Acta Oncologica ·Abdullah Alamro, Henrik Schultz	17
14	Surveillance following orchidectomy for stage I seminoma of the testis 1993 ·European Journal of Cancer ·Hans von der Maase, Lena Specht, Grete Krag Jacobsen, Anders Jakobsen, Ebbe Lindegaard Madsen, (unknown), Mikael Rørth, Henrik Schultz	186
15	A multicenter phase II study of carboplatin in advanced ovarian carcinoma: Final report 1992 ·Annals of Oncology ·Knut E. Kjørstad, Adrian L. Harris, K. Bertelsen, Mark Slevin, Henrik Schultz, Kristina Hellman, (unknown), Anne Marie Martin, Renzo Canetta	14
16	Neutron therapy in saudi arabia: An overview and results of dose searching study in head and neck cancer 1992 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Henrik Schultz, Khurshid Ahmad, (unknown), (unknown), H. Dobson, Edward Devol	1
17	Metastasis in skeletal muscle secondary to squamous‐cell carcinoma of the uterine cervix 1991 ·Acta Obstetricia Et Gynecologica Scandinavica ·(unknown), Jan Skovdal, Henrik Schultz	5
18	Surveillance alone versus radiotherapy after orchiectomy for clinical stage I nonseminomatous testicular cancer. Danish Testicular Cancer Study Group. 1991 ·Journal of Clinical Oncology ·Mikael Rørth, Grete Krag Jacobsen, Hans von der Maase, Ebbe Lindegaard Madsen, Ole S. Nielsen, M. G. Pedersen, Henrik Schultz	54
19	Nasopharyngeal carcinoma in Saudi Arabia: A retrospective study of 166 cases treated with curative intent 1988 ·International Journal of Radiation OncologyBiologyPhysics ·George E. Laramore, (unknown), Cedric A. Quick, Marwa Amer, (unknown), William Greer, Ezzat Mahboubi, (unknown), Henrik Schultz, (unknown)	30
20	Non-Seminomatous Testicular Germ Cell Tumours: Preliminary analysis of ongoing trials in the Dateca Study 1984 ·Acta Radiologica Oncology ·Mikael Rørth, Hans von der Maase, (unknown), Henrik Schultz, (unknown), (unknown)	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact